Skip to content

BioMedNews.org

Search
  • About
BiomedNews

Netherlands medical center to use microarray research

July 28, 2004 admin

The Erasmus Medical Center in Rotterdam (serving 3 million people) is implementing the use of Affymetrix microarray technology for every area of research. The goal is to take genetic and genomic research that is consistent and reproducible–as required for clinical trials–and translate it into clinical tools to improve patient care.

Post navigation

Previous PostWeight affects fertilityNext PostThis just in: Overeating is bad

Looking at how bioscience news affects business, higher education, government – and you and me

Recent Posts

  • New stem cell research: healing, infertility, transplants
  • Keeping stem cells at full potential
  • Battery-less pacemaker tests out
  • Seasonless broccoli – seeking solutions to food supply in global warming
  • New tool against MRSA – Stem cells in silver scaffolding
Facebooktwitterredditpinterestlinkedinmail
Facebooktwitterlinkedinrssyoutube

Archives

Tag cloud

  • Arthritis
  • Asbestos
  • Asthma
  • Biology
  • Biotechnology
  • Blood pressure
  • Blood test
  • Blood vessel
  • Brain tumor
  • Cancer
  • Cardiovascular Disorders
  • Cell (biology)
  • Clinical trial
  • Conditions and Diseases
  • diabetes
  • Dog
  • embryonic stem cells
  • Gene therapy
  • Health
  • Heart
  • Heart disease
  • Heart failure
  • Hydrogen sulfide
  • Hypertension
  • Lung cancer
  • Macular degeneration
  • Mesothelioma
  • Myocardial infarction
  • nanofibers
  • nanomedicine
  • Nanoparticle
  • nanoparticles
  • nanotechnology
  • National Institutes of Health
  • Nitric oxide
  • obesity
  • Parkinson's disease
  • Radiation therapy
  • statins
  • Stem cell
  • stem cell research
  • Stroke
  • Thrombus
  • Tissue (biology)

Archives

Proudly powered by WordPress
Please wait...

Subscribe to our newsletter

Want to be notified when our article is published? Enter your email address and name below to be the first to know.
SIGN UP FOR NEWSLETTER NOW